News

  • All
  • Asylia News
  • Nirogy News
  • Press Release
  • Sporos News
  • Stellanova News
  • Tvardi News
Tvardi News

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Read More →
Tvardi News

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

Read More →
Tvardi News

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research

Read More →
Nirogy News

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Read More →
Press Release

Sporos Bioventures Announces Formation of Strategic Advisory Board

Read More →
Sporos News

Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors

Read More →
Sporos News

Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer

Read More →
Tvardi News

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

Read More →
Press Release

Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing

Read More →
Asylia News

Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing

Read More →
Sporos News

Sporos Launches with $38.1 Million Series A Financing

Read More →
Nirogy News

Nirogy Therapeutics to Present at AACR Annual Meeting 2021

Read More →
Scroll to Top